Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours

British Journal of Surgery

Volumn 98, Issue 11, 2011, Pages 1561-1565

  Tanaka, K ^a   Kawaguchi, H ^a   Nakamura, Y ^a   Taguchi, K ^a   Nishiyama, K ^a   Ohno, S ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80053576295     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7639     Document Type: Article

References (19)

1. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, et al.,; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 4141-4149. (Pubitemid 35191016)
2. Lohrish C, Piccart M,. An overview of HER2. Semin Oncol 2001; 28: 3-11. (Pubitemid 34062043)
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
4. Joensuu H, Isola J, Lundin M, Slminen T, Holli V, Kataja V, et al., Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1 N0 M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9: 923-930. (Pubitemid 36323694)
5. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al., High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-5706.
6. Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, et al., A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 2010; 119: 653-661.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsh A, Untch M, Smith I, et al.,; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
8. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
9. Slamon D, Eiermann W, Robert N,. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. Cancer Res (Abstracts) 2009; 69 (Suppl): 500S.
10. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al.,; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36. (Pubitemid 46039831)
11. Viani G, Afonso S, Stefano E, De Fende LI, Soares FV,. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.
12. National Comprehensive Cancer Network (NCNN). NCNN Clinical Practice Guidelines in Oncology-v.2.2011. [accessed 1 February 2011].
13. Goldhirsch A, Ingle JN, Gelber D, Coates AS, Thurlimann B, Senn HJ,. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
14. Kataja V, Castiglione M,; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 10-14.
15. National Institutes of Health (NIH). NIH Guidelines. [accessed 1 February 2011].
16. McArthur HL, Mahoney K, Morris PG, Patil S, Jacks LM, Howard J, et al., Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers. J Clin Oncol (Abstracts) 2010; 28 (Suppl): 615.
17. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, et al., Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: a joint AERIO/REMAGUS study. J Clin Oncol (Abstracts) 2009; 27 (Suppl): 517.
18. Banerjee S, Smith IE,. Management of small HER2-positive breast cancers. Lancet Oncol 2010; 11: 1193-1199.
19. Joerger M, Thürlimann B, Houber J,. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol 2011; 22: 17-23.